2010
Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin
Reddy K, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, Mekeel K, Post D, Heilman R, Mulligan D. Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin. Transplantation Proceedings 2010, 42: 2006-2008. PMID: 20692393, DOI: 10.1016/j.transproceed.2010.05.090.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenal Cortex HormonesAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumCreatinineDrug Therapy, CombinationGlomerular Filtration RateGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKidney TransplantationMycophenolic AcidPancreas TransplantationPatient SelectionRetrospective StudiesConceptsRapid steroid taperAcute rejection episodesR-ATG groupR-ATGSimultaneous kidneySteroid taperBK nephropathyRejection episodesPancreas transplantationAlemtuzumab groupClinical acute rejection episodesRabbit antithymocyte globulin inductionAntithymocyte globulin inductionR-ATG inductionMean serum creatinineHistoric control groupPostoperative day 4Alemtuzumab inductionAntithymocyte globulinGlobulin inductionMaintenance immunosuppressionTransplant characteristicsGraft survivalCMV infectionCytomegalovirus infection
2009
Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match
Heilman R, Chakkera H, Mazur M, Petrides S, Moss A, Mekeel K, Mulligan D, Reddy K. Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match. Transplantation Proceedings 2009, 41: 303-306. PMID: 19249540, DOI: 10.1016/j.transproceed.2008.08.154.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumDrug Therapy, CombinationFollow-Up StudiesGraft SurvivalHistocompatibility TestingHumansImmunoglobulins, IntravenousImmunosuppressive AgentsKidney TransplantationPancreas TransplantationRetrospective StudiesSurvival AnalysisTime FactorsTreatment OutcomeConceptsAntibody-mediated rejectionLow-dose intravenous immunoglobulinAcute cellular rejectionIntravenous immunoglobulinStudy groupControl groupAllograft survivalMycophenolate mofetilRisk of AMRSimultaneous pancreas-kidney transplant recipientsPancreas-kidney transplant recipientsSimultaneous kidney-pancreas transplantationDose intravenous immunoglobulinKidney-pancreas transplantationPositive cross matchRabbit antithymocyte globulinActuarial patient survivalKidney allograft survivalKidney transplant recipientsPancreas allograft survivalAcute rejectionAntithymocyte globulinCellular rejectionSPKT recipientsKidney allografts
2007
Clinical factors associated with graft fibrosis in kidney‐transplant recipients on steroid‐avoidance immunosuppression
Heilman RL, Chakkera HA, Reddy KS, Colby TV, Moss AA, Williams JW, Mazur MJ, Petrides S, Mulligan DC. Clinical factors associated with graft fibrosis in kidney‐transplant recipients on steroid‐avoidance immunosuppression. Clinical Transplantation 2007, 22: 309-315. PMID: 18482051, DOI: 10.1111/j.1399-0012.2007.00786.x.Peer-Reviewed Original ResearchConceptsSteroid avoidance immunosuppressionKidney-pancreas transplant recipientsOne-year biopsyKidney transplant recipientsBK nephropathySerum creatinineProtocol biopsiesRecipient ageTransplant recipientsGraft fibrosisUnadjusted logistic regression analysisLower body mass indexMultivariate logistic regression modelCI scoresPrimary kidney transplantsPancreas transplant recipientsBody mass indexInterstitial cellular infiltrateLogistic regression analysisLogistic regression modelsAcute rejectionAntigen mismatchesAntithymocyte globulinGraft outcomeKidney transplant
2006
Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab
Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC. Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab. Transplantation Proceedings 2006, 38: 1307-1313. PMID: 16797289, DOI: 10.1016/j.transproceed.2006.02.116.Peer-Reviewed Original ResearchConceptsBiopsy-proven acute rejectionSteroid avoidance immunosuppressionKidney transplant recipientsAntithymocyte globulinAcute rejectionTransplant recipientsMonths posttransplantationAcute rejection-free survivalType 1 diabetes mellitusRabbit antithymocyte globulinRejection-free survivalAcute rejection riskInduction therapyMaintenance immunosuppressionProtocol biopsiesRapid discontinuationMost patientsDiabetes mellitusMedian timeLower incidenceRejection riskBasiliximabImmunosuppressionDay 4Overall risk